666例老年非瓣膜病心房颤动抗凝治疗现况调查

被引:16
作者
秦明照 [1 ]
张雪松 [2 ]
赵森 [3 ]
王宁 [1 ]
陈一文 [1 ]
孙颖 [4 ]
郑虹 [3 ]
马丽娜 [5 ]
张丽 [5 ]
孙静 [2 ]
安学志 [6 ]
牛红育 [7 ]
张洁 [8 ]
机构
[1] 首都医科大学附属北京同仁医院老年医学科
[2] 民航总医院
[3] 首都医科大学附属北京安贞医院
[4] 首都医科大学附属北京友谊医院
[5] 首都医科大学宣武医院
[6] 北京积水潭医院
[7] 首都医科大学附属北京朝阳医院
[8] 首都医科大学复兴医院
关键词
老年; 非瓣膜病心房颤动; 抗凝治疗;
D O I
10.15932/j.0253-9713.2016.10.003
中图分类号
R541.75 [];
学科分类号
摘要
总结调查老年非瓣膜病心房颤动患者的血栓栓塞风险、出血风险以及抗凝治疗现状。方法选取2012年5月-2013年9月在北京市8家三级综合医院心内科、老年医学科门诊或住院的老年非瓣膜病心房颤动患者666例,收集患者一般信息、合并疾病、抗栓治疗情况等资料,依据CHADS2、CHA2DS2-VASc评分评估血栓栓塞风险,HAS-BLED评分评估出血风险。比较不同栓塞危险分层的抗凝治疗情况。结果入选患者男416例,女250例,平均年龄(79.9±8.0)岁,其中≥80岁的高龄患者363例(54.5%)。合并高血压513例(77.0%),合并冠心病266例(39.9%),合并缺血性卒中病史患者243例(36.5%)。CHADS2评分平均为3.4±1.5,≥2分者581例(87.2%)。CHA2DS2-VASc评分平均为5.5±1.9,2分及以上者647例(97.1%)。HAS-BLED评分平均1.7±0.9,≥3分者113例(17.0%)。CHADS2≥2分的血栓栓塞高危患者中,21.5%(125/581)接受抗凝治疗,55.1%(320/581)接受抗血小板治疗,23.4%(136/581)未接受任何抗栓治疗。CHA2DS2-VASc≥2分的血栓栓塞高危患者中,23.3%(151/647)接受抗凝治疗,54.3%(351/647)接受抗血小板治疗,22.4%(145/647)未接受任何抗栓治疗。结论老年房颤患者合并疾病较多,且多处于血栓栓塞高风险状态。但接受抗凝治疗比例低,仍以抗血小板治疗为主。
引用
收藏
页码:975 / 979
页数:5
相关论文
共 12 条
[1]
Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation The Chinese Atrial Fibrillation Registry Study [J].
Chang, San-Shuai ;
Dong, Jian-Zeng ;
Ma, Chang-Sheng ;
Du, Xin ;
Wu, Jia-Hui ;
Tang, Ri-Bo ;
Xia, Shi-Jun ;
Guo, Xue-Yuan ;
Yu, Rong-Hui ;
Long, De-Yong ;
Bai, Rong ;
Liu, Nian ;
Sang, Cai-Hua ;
Jiang, Chen-Xi ;
Liu, Xiao-Hui ;
Pan, Jian-Hong ;
Lip, Gregory Y. H. .
STROKE, 2016, 47 (07) :1803-1810
[2]
Atrial Fibrillation Is Associated With a Worse 90-Day Outcome Than Other Cardioembolic Stroke Subtypes [J].
Henninger, Nils ;
Goddeau, Richard P., Jr. ;
Karmarkar, Ameeta ;
Helenius, Johanna ;
McManus, David D. .
STROKE, 2016, 47 (06) :1486-U250
[3]
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.[J].Craig T. January;L. Samuel Wann;Joseph S. Alpert;Hugh Calkins;Joaquin E. Cigarroa;Joseph C. Cleveland;Jamie B. Conti;Patrick T. Ellinor;Michael D. Ezekowitz;Michael E. Field;Katherine T. Murray;Ralph L. Sacco;William G. Stevenson;Patrick J. Tchou;Cynthia M
[4]
Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation A Report From the Swedish Atrial Fibrillation Cohort Study [J].
Friberg, Leif ;
Rosenqvist, Marten ;
Lip, Gregory Y. H. .
CIRCULATION, 2012, 125 (19) :2298-+
[5]
Age as a Risk Factor for Stroke in Atrial Fibrillation Patients.[J].Ricarda Marinigh;Gregory Y.H. Lip;Nicola Fiotti;Carlo Giansante;Deirdre A. Lane.Journal of the American College of Cardiology.2010, 11
[6]
Epidemiology, risk factors for stroke, and management of atrial fibrillation in China [J].
Hu, Dayi ;
Sun, Yihong .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (10) :865-868
[7]
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial [J].
Mant, Jonathan ;
Hobbs, F. D. Richard ;
Fletcher, Kate ;
Roalfe, Andrea ;
Fitzmaurice, David ;
Lip, Gregory Y. H. ;
Murray, Ellen .
LANCET, 2007, 370 (9586) :493-503
[8]
Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation [J].
Birman-Deych, E ;
Radford, MJ ;
Nilasena, DS ;
Gage, BF .
STROKE, 2006, 37 (04) :1070-1074
[9]
Stroke severity in atrial fibrillation - The Framingham study [J].
Lin, HJ ;
Wolf, PA ;
KellyHayes, M ;
Belser, AS ;
Kase, CS ;
Benjamin, EJ ;
DAgostino, RB .
STROKE, 1996, 27 (10) :1760-1764
[10]
非瓣膜病心房颤动患者全球抗凝注册研究中国亚组基线数据分析.[J].孙艺红;胡大一;.中华心血管病杂志.2014, 10